Lee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China

Reuters

Jul 31

Lee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China

Lee's Pharmaceutical Holdings Limited has announced that its subsidiary, China Oncology Focus Limited, has received regulatory approval for Socazolimab, an investigational oncology drug product, from the National Medical Products Administration (NMPA) in Mainland China. This approval allows the marketing of Socazolimab in combination with chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The approval is based on the positive results of a Phase III clinical trial led by Prof. Shun Lu from Shanghai Chest Hospital, which demonstrated significant overall survival benefits for patients treated with Socazolimab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief on July 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555007092"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555007092\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555007092?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555007092","market":"us","top_or_hot":-1,"title":"Lee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lee's Pharmaceutical Holdings Limited has announced that its subsidiary, China Oncology Focus Limited, has received regulatory approval for Socazolimab, an investigational oncology drug product, from the National Medical Products Administration (NMPA) in Mainland China. This approval allows the marketing of Socazolimab in combination with chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The approval is based on the positive results of a Phase III clinical trial led by Prof. Shun Lu from Shanghai Chest Hospital, which demonstrated significant overall survival benefits for patients treated with Socazolimab.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lee's Pharmaceutical Holdings Limited has announced that its subsidiary, China Oncology Focus Limited, has received regulatory approval for Socazolimab, an investigational oncology drug product, from the National Medical Products Administration (NMPA) in Mainland China. This approval allows the marketing of Socazolimab in combination with chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The approval is based on the positive results of a Phase III clinical trial led by Prof. Shun Lu from Shanghai Chest Hospital, which demonstrated significant overall survival benefits for patients treated with Socazolimab.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00950","symbol_name":"李氏大药厂","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL3YpFq8:1","article_id":"2555007092","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555007092","pubTimestamp":1753951220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China. Lee's Pharmaceutical Holdings Limited has announced that its subsidiary, China Oncology Focus Limited, has received regulatory approval for Socazolimab, an investigational oncology drug product, from the National Medical Products Administration  in Mainland China. This approval allows the marketing of Socazolimab in combination with chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer . The approval is based on the positive results of a Phase III clinical trial led by Prof. Shun Lu from Shanghai Chest Hospital, which demonstrated significant overall survival benefits for patients treated with Socazolimab.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00950":"李氏大药厂","BK1191":"制药"},"translate_title":"李氏药业集团有限公司索卡唑单抗在中国内地一线治疗广泛期小细胞肺癌获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00950":0.9},"content_text":"Lee's Pharmaceutical Holdings Limited Secures Approval for Socazolimab in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in Mainland China\n    \n\n        Lee's Pharmaceutical Holdings Limited has announced that its subsidiary, China Oncology Focus Limited, has received regulatory approval for Socazolimab, an investigational oncology drug product, from the National Medical Products Administration (NMPA) in Mainland China. This approval allows the marketing of Socazolimab in combination with chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The approval is based on the positive results of a Phase III clinical trial led by Prof. Shun Lu from Shanghai Chest Hospital, which demonstrated significant overall survival benefits for patients treated with Socazolimab.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief on July 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}